| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 23.14M | 22.61M | 20.45M | 19.10M | 18.05M | 21.01M |
| Gross Profit | 19.46M | 18.92M | 17.04M | 15.79M | 14.86M | 13.10M |
| EBITDA | 8.70M | 8.95M | 7.61M | 7.11M | 5.38M | 5.41M |
| Net Income | 7.13M | 6.98M | 5.96M | 5.59M | 4.00M | 4.12M |
Balance Sheet | ||||||
| Total Assets | 55.61M | 55.33M | 51.60M | 50.58M | 49.32M | 55.05M |
| Cash, Cash Equivalents and Short-Term Investments | 28.79M | 28.57M | 25.15M | 23.99M | 21.46M | 24.07M |
| Total Debt | 457.30K | 509.97K | 545.10K | 747.11K | 2.97M | 6.70M |
| Total Liabilities | 5.44M | 5.81M | 4.74M | 4.70M | 6.42M | 9.91M |
| Stockholders Equity | 50.17M | 49.52M | 46.85M | 45.88M | 42.90M | 45.14M |
Cash Flow | ||||||
| Free Cash Flow | 8.06M | 8.40M | 6.89M | 7.96M | 6.05M | 5.08M |
| Operating Cash Flow | 8.09M | 8.42M | 6.96M | 8.86M | 6.10M | 5.40M |
| Investing Cash Flow | -54.28K | 169.00 | -100.71K | -903.19K | 1.32M | -318.87K |
| Financing Cash Flow | -5.03M | -5.01M | -5.70M | -5.43M | -10.03M | -1.36M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | $255.12M | 38.69 | 14.60% | 0.54% | 11.05% | 18.55% | |
66 Neutral | $264.32M | 1.58 | ― | 13.13% | -19.17% | 308.81% | |
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% | |
57 Neutral | $606.12M | ― | -28.65% | ― | 16.40% | 22.80% | |
54 Neutral | $230.02M | ― | -20.20% | ― | -6.23% | 28.57% | |
53 Neutral | $274.34M | ― | -25.48% | ― | -24.30% | -181.62% | |
48 Neutral | $256.48M | ― | -4.88% | ― | 0.25% | 92.10% |
On November 19, 2025, ReposiTrak, Inc. held its Annual Meeting of Stockholders where several key proposals were voted on. The election of directors resulted in the re-election of all nominees, and stockholders approved the executive compensation on a non-binding advisory basis. Additionally, it was decided that the advisory vote on executive compensation will occur every three years, and Haynie & Company was ratified as the independent auditor for the fiscal year ending June 30, 2026.
The most recent analyst rating on (TRAK) stock is a Buy with a $16.50 price target. To see the full list of analyst forecasts on ReposiTrak stock, see the TRAK Stock Forecast page.
ReposiTrak reported a 10% increase in revenue to $6.0 million for the first fiscal quarter ending September 30, 2025, with a 13% rise in earnings per share. The company maintained a strong financial position with $29 million in cash and no debt, while also increasing its quarterly dividend by 10%. The company’s focus on automation and operational efficiency is expected to support smaller market participants and enhance profitability, strengthening its competitive position in the traceability and compliance market.
The most recent analyst rating on (TRAK) stock is a Buy with a $16.50 price target. To see the full list of analyst forecasts on ReposiTrak stock, see the TRAK Stock Forecast page.
The recent earnings call from ReposiTrak painted a generally positive picture of the company’s financial health and future prospects. The management expressed optimism due to significant revenue growth, increased profitability, and strong cash management. However, they also acknowledged challenges such as reduced cash from operations, increased operating expenses, higher taxes, and data integrity issues. Despite these hurdles, the company’s strategic initiatives and market positioning suggest a promising future.
ReposiTrak, a leader in food traceability and regulatory compliance, offers cloud-based solutions for retailers, suppliers, and wholesalers to enhance operational controls and ensure regulatory compliance. The company recently reported a robust financial performance for the first fiscal quarter of 2026, with a 10% increase in revenue to $6.0 million and a 13% rise in earnings per share. ReposiTrak’s financial highlights include a 28% increase in operating income and a 9% rise in net income, ending the quarter with $29 million in cash and no debt. The company also declared a quarterly dividend, marking the third consecutive 10% increase since its inception.
Repositrak’s recent earnings call painted a picture of robust financial health, underscored by impressive revenue and profitability growth. The company demonstrated effective cash management and delivered positive returns to shareholders. However, the call also highlighted concerns about rising operating expenses and the potential impact of tariffs on future performance.
ReposiTrak reported a successful fiscal year ending June 30, 2025, with an 11% increase in full-year revenue to $22.6 million and a 17% rise in net income to $7.0 million. The company has shifted its strategy to a supplier-centric model, enhancing engagement with individual suppliers and expanding cross-selling opportunities, which has contributed to its revenue growth and improved financial metrics, such as a 24% increase in operating income. ReposiTrak ended the year with $28.6 million in cash and no debt, and announced a 10% increase in its quarterly dividend, reflecting strong financial health and a commitment to returning capital to shareholders.
The most recent analyst rating on (TRAK) stock is a Buy with a $18.50 price target. To see the full list of analyst forecasts on ReposiTrak stock, see the TRAK Stock Forecast page.
ReposiTrak, a leader in food traceability and regulatory compliance solutions, offers a comprehensive suite of cloud-based applications for retailers, suppliers, and wholesalers to enhance operational controls and ensure compliance. The company recently reported a robust financial performance for the fiscal year ending June 30, 2025, with significant increases in revenue and net income.
On September 19, 2025, ReposiTrak, Inc. announced a quarterly cash dividend of $0.02 per share, payable on November 14, 2025, to shareholders of record as of September 30, 2025. This marks the third increase in the company’s dividend since its establishment, reflecting ReposiTrak’s ongoing commitment to returning value to its shareholders.
The most recent analyst rating on (TRAK) stock is a Buy with a $18.50 price target. To see the full list of analyst forecasts on ReposiTrak stock, see the TRAK Stock Forecast page.